Innovent Biologics, Inc. (1801.HK) HKSE

86.85

-1.9(-2.14%)

Updated at October 17 04:08PM

Currency In HKD

Innovent Biologics, Inc.

Address

168 Dongping Street

Suzhou, 215123

China

Phone

86 512 6956 6088

Sector

Healthcare

Industry

Biotechnology

Employees

5659

First IPO Date

October 31, 2018

Key Executives

NameTitlePayYear Born
Dr. De-Chao Yu Ph.D.Co-Founder, Chairman & Chief Executive Officer44M1964
Ms. Qian ZhangChief People Officer, GM & Executive Director3.03M1987
Mr. Hao Xi EdeExecutive Director & Fund Managing Partner7.75M1959
Ms. Fei You CPAChief Financial Officer01979
Dr. Samuel Suhua Zhang M.B.A., Ph.D.Global Chief Business Officer01968
Dr. Raj Dhodda Ph.D.Senior Vice President0N/A
Mr. Blake SalisburySenior Vice President0N/A
Mr. Min LiuChief Commercial Officer01973
Dr. Hui Zhou Ph.D.Senior Vice President0N/A
Ms. Cong Ding J.D.General Counsel0N/A

Description

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.